Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Experimental evaluation of pathway-specific modulation in cellular energy systems
Currently, NS-2330 is in Phase II clinical trials for AD and undergoing a Phase II tolerability trial for PD patients with dyskinesia
This interaction results in the formation of a complex that suppresses the ubiquitination and subsequent degradation of the transcription factor BACH1
2015 Nov 5;6:264
Importantly, Dihexa simultaneously increases expression of anti-inflammatory interleukin-10 (IL-10), suggesting the peptide actively shifts the neuroinflammatory balance toward resolution rather than simply suppressing inflammation
US$ 27.38
US$ 21.84
US$ 25.92
US$ 24.90
US$ 27.31
